Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance

Pashalina Kehagias(Université Libre de Bruxelles), Alain Hendlisz(London Cancer)

Cells

November 18, 2022

10.3390/cells11223663

Cited by 13

Related Papers

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

|Journal of Clinical Oncology|2018|2.1k

Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

|The Oncologist|2007|418

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

|Annals of Oncology|2022|253